Tech Enhanced Investing

HCL Technologies was trading at RS 1453.55, up by 3.15 points or 0.22% compared to its previous closing of RS 1450.40 on the BSE.

The stock opened at RS 1449.75 and touched an intraday high of RS 1455.30 and a low of RS 1431.40. A total of 20,377 shares were traded on the counter so far.

The BSE Group ‘A’ stock with a face value of RS 2 recorded a 52-week high of RS 1770.00 on February 3, 2026, and a 52-week low of RS 1304.00 on April 7, 2025. Over the past week, the stock’s high and low stood at RS 1510.50 and RS 1431.40, respectively. The company’s current market capitalization stands at RS 393779.94 crore.

In terms of shareholding pattern, promoters hold 60.81% stake in the company, while institutional investors and non-institutional investors hold 34.62% and 4.57%, respectively.

Meanwhile, HCL Tech has unveiled VisionX 2.0, an enhanced version of its multi-modal AI edge platform designed to deliver real-time intelligence, improved safety and operational efficiency across mission-critical industrial environments. The upgraded platform builds upon the company’s Intelligent Secure Edge capabilities by integrating advanced computer vision, Vision Language Models (VLMs), multi-modal fusion and edge-optimized generative AI.

VisionX 2.0 leverages the NVIDIA physical AI computing stack, including NVIDIA Blueprint for Video Search and Summarization (VSS), NVIDIA DeepStream, NVIDIA Cosmos Reason VLM and NVIDIA TAO for post-training vision models, ensuring high-performance AI deployment.

Designed for demanding industrial applications, the platform introduces innovations such as On-Prem Edge AI Performance, a Multi-Modal AIoT Engine, VSS Event Reviewer for reliable verification, Zero-Trust Edge Security and seamless integration capabilities.

By utilizing NVIDIA Metropolis and NVIDIA Omniverse, VisionX 2.0 offers enterprises a scalable and secure foundation to implement high-performance AI at the industrial edge. The company’s Physical AI portfolio combines Kinetic AI (Cognitive Robotics), Autonomous Systems and Edge AI to enhance productivity, resilience and sustainability in real-world environments.

HCL Technologies is engaged in delivering IT and business services, engineering and R&D solutions, along with modernized software products and IP-led offerings.

Rail Vikas Nigam Limited is currently trading at RS 308.40, rising by 1.65 points or 0.54% from its previous close of RS 306.75 on the Bombay Stock Exchange (BSE).

The stock opened at RS 306.00 and touched an intraday high of RS 310.50 and a low of RS 303.00. A total of 2,43,994 shares have been traded so far.

The BSE Group ‘A’ stock with a face value of RS 10 hit a 52-week high of RS 448.00 on 20-May-2025 and a 52-week low of RS 295.25 on 07-Apr-2025. Over the past week, the stock recorded a high of RS 314.40 and a low of RS 303.00. The company’s current market capitalization stands at RS 64,197.77 crore.

Promoters hold 72.84% stake in the company, while Institutional and Non-Institutional investors hold 11.37% and 15.79%, respectively.

Rail Vikas Nigam has executed a Strategic Joint Venture Shareholders’ Agreement with Texmaco Rail & Engineering for the incorporation and operation of a joint venture company. The partnership will focus on advanced rolling stock segments, lifecycle maintenance, asset management solutions, and large-scale EPC and turnkey infrastructure projects in India and overseas markets.

The proposed joint venture is expected to boost large-scale industrial activity, strengthen domestic MSME ecosystems, and generate thousands of skilled jobs across India’s manufacturing corridors. It will also incorporate sustainable practices, including renewable energy integration and circular production systems.

RVNL operates as an extended arm of the Ministry of Railways and undertakes execution of diverse railway infrastructure projects such as new railway lines, doubling, gauge conversion, electrification, metro projects, workshops, major bridges, cable-stayed bridges, and institutional buildings.

Paras Defence and Space Technologies is currently trading at RS 634.05, registering a gain of 3.80 points or 0.60% from its previous close of RS 630.25 on the BSE.

The stock opened at RS 630.30 and touched an intraday high of RS 637.45 and a low of RS 629.40. A total of 305 shares have been traded so far.

The BSE Group ‘A’ stock with a face value of RS 5 hit a 52-week high of RS 971.80 on May 19, 2025, and a 52-week low of RS 401.00 on April 07, 2025. Over the past week, the stock recorded a high of RS 652.70 and a low of RS 629.40. The company’s current market capitalization stands at RS 5079.02 crore.

Promoters hold 53.20% stake in the company, while institutional investors and non-institutional investors hold 6.21% and 40.60%, respectively.

The company has completed the acquisition of a 49% equity stake in Himanshi Thermal Solutions from DefSpace Technologies on February 19, 2026.

Following the transaction, Himanshi Thermal Solutions has become an associate company of Paras Defence and Space Technologies. The acquisition aligns with the company’s strategic expansion plans and is expected to generate new growth opportunities and synergies at the group level, strengthening the overall business portfolio.

Paras Defence and Space Technologies is engaged in the design, development, manufacturing, and testing of a wide range of defence and space engineering products and solutions.

Fabtech Technologies Cleanrooms is currently trading at RS 290.00 on the BSE, marking a gain of 7.50 points or 2.65% compared to its previous closing of RS 282.50.

The stock opened at RS 290.00 and touched an intraday high and low of RS 290.00 each. A total of 2,000 shares have been traded so far on the counter.

The BSE Group ‘M’ stock, with a face value of RS 10, had earlier recorded a 52-week high of RS 470.00 on July 21, 2025, and a 52-week low of RS 161.50 on January 10, 2026. Over the past week, the stock registered a high of RS 335.00 and a low of RS 301.95. The company’s current market capitalization stands at RS 357.26 crore.

In terms of shareholding pattern, promoters hold 68.49% stake in the company, while institutional investors and non-institutional investors hold 8.97% and 22.54% respectively.

In a key development, the company’s Board of Directors has approved the acquisition of 38,673 equity shares in Advantek Air Systems. The decision was taken at the board meeting held on February 12, 2026. The acquisition, aligned with the company’s core business operations, is aimed at supporting business expansion.

The transaction will be completed for a total cash consideration of RS 2.54 crore.

Fabtech Technologies Cleanrooms operates in the manufacturing of pre-engineered and pre-fabricated modular panels and doors used for developing internal infrastructure for pharmaceutical and allied industries.

Shares of Alkem Laboratories were trading at RS 5460.05, up by 58.50 points or 1.08% from the previous closing of RS 5401.55 on the BSE.

The stock opened at RS 5429.20 and touched an intraday high of RS 5538.35 and a low of RS 5384.50. A total of 1,894 shares were traded on the counter so far.

The BSE Group ‘A’ stock with a face value of RS 2 hit its 52-week high of RS 5933.00 on January 13, 2026, and a 52-week low of RS 4498.90 on February 28, 2025. Over the past week, the stock recorded a high of RS 5910.00 and a low of RS 5332.45. The company’s current market capitalization stands at RS 65677.05 crore.

In terms of shareholding, promoters hold 51.20% stake in the company, while Institutions and Non-Institutions account for 31.51% and 17.30%, respectively.

On the financial front, Alkem Laboratories reported a 13.96% decline in its standalone net profit at RS 622.14 crore for the third quarter ended December 31, 2025, compared to RS 723.12 crore in the same quarter of the previous year. However, the company’s total income rose 6.79% to RS 2622.80 crore in Q3FY26, up from RS 2456.01 crore in the corresponding quarter last year.

On a consolidated basis, the company posted a marginal increase in net profit to RS 636.02 crore for the quarter ended December 31, 2025, as against RS 625.82 crore in the year-ago period. Consolidated total income grew 11.90% to RS 3879.92 crore in Q3FY26, compared to RS 3467.27 crore in the corresponding quarter of the previous year.

Techknowgreen Solutions is currently trading at RS 113.00, up by 2.00 points or 1.80% from its previous closing of RS 111.00 on the BSE.

The stock opened at RS 106.20 and touched an intraday high of RS 113.00 and a low of RS 106.20. So far, 3,600 shares have been traded on the counter.

The BSE Group ‘M’ stock with a face value of RS 10 reached its 52-week high of RS 207.00 on February 14, 2025, and a 52-week low of RS 98.00 on February 02, 2026. During the past week, the stock recorded a high of RS 120.70 and a low of RS 105.00. The company’s current market capitalization stands at RS 83.42 crore.

Promoters hold a 65.58% stake in the company, while non-institutional investors account for 34.42% shareholding.

In a significant development, Techknowgreen Solutions has secured a work order worth $190,598.00 (including tax) from Sterling & Wilson Data Center, Riyadh, Kingdom of Saudi Arabia. The contract involves comprehensive Environmental Project Criteria evaluation and implementation for the ‘RUH-East Data Center’ project in Riyadh. The project is scheduled to be completed within 18 months.

Techknowgreen Solutions operates in the field of environmental and infrastructure planning consultancy, offering sustainable and economically viable solutions to environmental and climate change challenges.

Zydus Lifesciences shares were trading at RS 910.65, rising by 5.80 points or 0.64% from the previous close of RS 904.85 on the BSE. The stock opened at RS 904.80 and touched an intraday high of RS 916.00 and a low of RS 904.25. A total of 3,360 shares changed hands on the counter.

The BSE Group ‘A’ stock with a face value of RS 1 hit a 52-week high of RS 1059.00 on 19-Sep-2025 and a 52-week low of RS 797.05 on 07-Apr-2025. Over the past week, the scrip recorded a high of RS 933.40 and a low of RS 882.00. The company’s current market capitalisation stands at RS 91788.66 crore.

Promoters hold a 75.00% stake in the company, while institutional and non-institutional investors own 18.15% and 6.85%, respectively.

In a key development, the company has received final approval from the United States Food and Drug Administration (USFDA) for Ammonium Lactate Cream, 12% (USRLD: Lac-Hydrin Cream, 12%).

Ammonium lactate cream, 12% is a topical prescription medicine indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris, a hereditary skin condition. The formulation works by enhancing skin hydration and, as an alpha-hydroxy acid, helps reduce itching, soften the skin, and minimise scaling.

The product will be manufactured at the group’s topical manufacturing facility in Changodar, Ahmedabad, and marketed in the US by Viona Pharmaceuticals Inc.. According to IQVIA MAT December 2025 data, the product recorded annual sales of $15 million in the United States.

With this approval, the group now has 430 approvals and has filed 505 ANDAs since initiating the filing process in FY 2003-04.

Zydus Lifesciences, formerly known as Cadila Healthcare, is an integrated pharmaceutical company engaged across the entire value chain, including research, development, manufacturing, marketing, and distribution of pharmaceutical products.

Natco Pharma shares surged sharply on the BSE, currently trading at RS 885.35, up by 63.25 points or 7.69% compared to its previous close of RS 822.10.

The stock opened at RS 825.05 and touched an intraday high of RS 895.00 and a low of RS 825.05. A total of 382 shares have been traded so far on the counter.

The BSE Group ‘A’ stock with a face value of RS 2 had earlier touched a 52-week high of RS 1059.60 on July 24, 2025, and a 52-week low of RS 660.05 on April 7, 2025. Over the past week, the scrip recorded a high of RS 895.00 and a low of RS 815.05. The company’s current market capitalization stands at RS 14724.62 crore.

In terms of shareholding pattern, promoters hold 49.48% stake in the company, while Institutional investors and Non-Institutional investors hold 20.54% and 29.97% respectively.

The rally comes after the company received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market a generic version of Semaglutide Injection in India. The company plans to launch the product in March 2026. Semaglutide is prescribed for adults with inadequately controlled type 2 diabetes mellitus and is used alongside diet and exercise.

Natco Pharma was originally incorporated as a private company and operates in the research, development, manufacturing, and marketing of pharmaceutical substances and finished dosage formulations for both domestic and international markets.

Hexaware Technologies surged 5.54% to trade at RS 574.10, rising by 30.15 points from its previous closing of RS 543.95 on the Bombay Stock Exchange (BSE).

The stock opened at RS 526.80 and touched an intraday high of RS 580.40 and a low of RS 521.25. A total of 73,280 shares were traded on the counter during the session.

The BSE Group ‘A’ stock with a face value of RS 1 had earlier hit a 52-week high of RS 900.15 on July 9, 2025, and a 52-week low of RS 521.25 on February 13, 2026. Over the past week, the stock recorded a high of RS 622.15 and a low of RS 521.25. The company’s current market capitalization stands at RS 33,193.44 crore.

In terms of shareholding pattern, promoters hold a 74.30% stake in the company, while institutional investors and non-institutional investors account for 19.46% and 6.23%, respectively.

Hexaware Technologies has announced a strategic partnership with CareInsight, combining AI-native healthcare platforms with advanced AI and digital transformation expertise. The collaboration aims to deliver outcome-driven, production-grade AI solutions at scale for healthcare organizations, focusing on measurable improvements in operations, decision-making, and patient care delivery.

The partnership is structured to enable healthcare organizations to deploy AI in real-world settings by facilitating integrated data flows, operational intelligence, and outcome-focused applications across the healthcare continuum. By leveraging CareInsight’s AI platforms alongside Hexaware’s implementation and transformation capabilities, the alliance seeks to reduce administrative complexities, enhance operational coordination, and support faster, data-driven decision-making.

Through this collaboration, both companies aim to help healthcare providers transform AI into a practical, everyday advantage—driving smarter decisions, streamlined operations, and improved patient experiences at scale.

Hexaware Technologies is a global digital and technology services company with artificial intelligence at its core, serving a diverse client base across the Americas, Europe, and the Asia-Pacific region, including India and the Middle East.

Hindustan Aeronautics Limited shares were trading at RS 4184.45, gaining 25.80 points or 0.62% from the previous close of RS 4158.65 on the Bombay Stock Exchange (BSE).

The stock opened at RS 4199.80 and moved between an intraday high of RS 4222.35 and a low of RS 4156.05. A total of 58,224 shares were traded on the counter during the session so far.

The BSE Group ‘A’ stock, with a face value of RS 5, had touched a 52-week high of RS 5166.00 on May 16, 2025, and a 52-week low of RS 3045.95 on March 3, 2025. Over the past week, the stock recorded a high of RS 4222.35 and a low of RS 4015.00. The company’s current market capitalization stands at RS 279551.29 crore.

In terms of shareholding pattern, promoters hold 71.64% stake in the company, while institutional investors and non-institutional investors account for 20.60% and 7.76%, respectively.

For the third quarter ended December 31, 2025, the company reported a 29.26% increase in standalone net profit at RS 1,851.72 crore, compared to RS 1,432.60 crore in the corresponding quarter of the previous year. Total income rose 13.50% to RS 8,612.38 crore in Q3FY26, as against RS 7,588.08 crore in the same period last year.

On a consolidated basis, net profit surged 29.65% to RS 1,866.68 crore for the quarter ended December 31, 2025, compared to RS 1,439.83 crore in the year-ago period. Consolidated total income increased 13.49% to RS 8,612.60 crore in Q3FY26, up from RS 7,588.71 crore in the corresponding quarter of the previous fiscal.